Promontory Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-11-15
- Employees
- 11
- Market Cap
- -
- Website
- http://www.phosplatin.com
Clinical Trials
4
Active:2
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)phase_1_2
1 (25.0%)Phase 2
1 (25.0%)A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Biological: avelumab
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Promontory Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT03409458
- Locations
- 🇺🇸
Arizona, Phoenix, Arizona, United States
🇺🇸Colorado, Aurora, Colorado, United States
🇺🇸Florida, Jacksonville, Florida, United States
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Promontory Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03288480
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Phase 2
Active, not recruiting
- Conditions
- Advanced Solid TumorsmCRPCProstatic NeoplasmsGenital Neoplasms, MaleNeoplasms by SiteCRPCMetastatic Castrate-resistant Prostate CancerPT-112Urogenital Neoplasms
- Interventions
- Drug: PT-112 Injection
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Promontory Therapeutics Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT02266745
- Locations
- 🇺🇸
Arizona, Phoenix, Arizona, United States
🇺🇸Tucson, Tucson, Arizona, United States
🇺🇸Duarte, Duarte, California, United States
News
No news found